Statement of Ownership (sc 13g)

Date : 11/26/2019 @ 10:26PM
Source : Edgar (US Regulatory)
Stock : Onconova Therapeutics Inc (ONTX)
Quote : 0.3376  -0.0124 (-3.54%) @ 12:59AM
Onconova Therapeutics share price Chart
After Hours
Last Trade
Last $ 0.34 ◊ 0.00 (0.00%)

Statement of Ownership (sc 13g)

240.13d-102 Schedule 13G - Information to be included in statements filed
pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
filed pursuant to 240.13d-2.
Securities and Exchange Commission, Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No._)*
(Name of Issuer)
Onconova Therapeutics, Inc.
(Title of Class of Securities)
Common Stock, Par Value $0.01 Per Share

(CUSIP Number)

68232V405

(Date of Event Which Requires Filing of this Statement)
November 25, 2019

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[  ] Rule 13d-1(b)
[ x ] Rule 13d-1(c)
[  ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see
the Notes).


CUSIP No. 68232V405
(1) Names of reporting persons    Point72 Asset Management, L.P.
 
(2) Check the appropriate box if a member of a group
(a)
(see instructions)
(b)X
(3) SEC use only
 
(4) Citizenship or place of organization  Delaware
 
Number of shares beneficially owned by each reporting person with:
 
(5) Sole voting power                  0
 
(6) Shared voting power              3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(7) Sole dispositive power           0
 
(8) Shared dispositive power       3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(9) Aggregate amount beneficially owned by each reporting person
3,230,434 shares of Common Stock (see Item 4)
3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(10) Check if the aggregate amount in Row (9) excludes certain shares
(see instructions)
 
(11) Percent of class represented by amount in Row (9)   9.99% (see Item 4)
 
(12) Type of reporting person (see instructions)     PN
 

* As more fully described in Item 4, the Warrants are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blocker.  However, as more fully described in Item 4, the shares of Common Stock reported in rows (6), (8) and (9) includes the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such blocker.  Therefore, the actual number of shares of Common Stock beneficially owned by such reporting person, after giving effect to such blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9).

CUSIP No. 68232V405
(1) Names of reporting persons    Point72 Capital Advisors, Inc.
 
(2) Check the appropriate box if a member of a group
(a)
(see instructions)
(b)X
(3) SEC use only
 
(4) Citizenship or place of organization  Delaware
 
Number of shares beneficially owned by each reporting person with:
 
(5) Sole voting power                  0
 
(6) Shared voting power              3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(7) Sole dispositive power           0
 
(8) Shared dispositive power       3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(9) Aggregate amount beneficially owned by each reporting person
3,230,434 shares of Common Stock (see Item 4)
3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(10) Check if the aggregate amount in Row (9) excludes certain shares
(see instructions)
 
(11) Percent of class represented by amount in Row (9)   9.99% (see Item 4)
 
(12) Type of reporting person (see instructions)     CO
 

* As more fully described in Item 4, the Warrants are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blocker.  However, as more fully described in Item 4, the shares of Common Stock reported in rows (6), (8) and (9) includes the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such blocker.  Therefore, the actual number of shares of Common Stock beneficially owned by such reporting person, after giving effect to such blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9).

CUSIP No. 68232V405
(1) Names of reporting persons    Steven A. Cohen
 
(2) Check the appropriate box if a member of a group
(a)
(see instructions)
(b)X
(3) SEC use only
 
(4) Citizenship or place of organization  United States
 
Number of shares beneficially owned by each reporting person with:
 
(5) Sole voting power                  0
 
(6) Shared voting power              3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(7) Sole dispositive power           0
 
(8) Shared dispositive power       3,230,434 shares of Common Stock (see Item 4)
     3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(9) Aggregate amount beneficially owned by each reporting person
3,230,434 shares of Common Stock (see Item 4)
3,000,000 shares of Common Stock issuable upon exercise of Warrants (see Item 4)*
 
(10) Check if the aggregate amount in Row (9) excludes certain shares
(see instructions)
 
(11) Percent of class represented by amount in Row (9)  9.99% (see Item 4)
 
(12) Type of reporting person (see instructions)     IN
 

* As more fully described in Item 4, the Warrants are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blocker.  However, as more fully described in Item 4, the shares of Common Stock reported in rows (6), (8) and (9) includes the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such blocker.  Therefore, the actual number of shares of Common Stock beneficially owned by such reporting person, after giving effect to such blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9).

Item 1(a) Name of issuer:
Onconova Therapeutics,Inc.
Item 1(b) Address of issuer's principal executive offices:
375 Pheasant Run, Newtown, PA 18940
2(a) Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
Management”) with respect to shares of common stock, par value $0.01 per
share (“Common Stock”), of the Issuer held by an investment fund it manages;
(ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
respect to Common Stock held by an investment fund managed by Point72 Asset
Management and; (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Common Stock
beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered
into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as
Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in
accordance with the provisions of Rule 13d-1(k) of the Act.
2(b) Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management,
Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
Stamford, CT 06902.
2(c) Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors
Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
2(d) Title of class of securities:
Common Stock, par value $0.01 per share
2(e) CUSIP Number:
68232V405

Item 3.

Not applicable


Item 4. Ownership

As of the close of business on November 25, 2019:

1. Point72 Asset Management, L.P.
(a) Amount beneficially owned: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants
(b) Percent of class: 9.99%          
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants          
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants.

2. Point72 Capital Advisors, Inc.
(a) Amount beneficially owned: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants
(b) Percent of class: 9.99%          
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants          
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants.

3. Steven A. Cohen
(a) Amount beneficially owned: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants
(b) Percent of class: 9.99%          
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants          
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 3,230,434 shares of Common Stock and, subject to a 9.99% blocker described below, 3,000,000 shares of Common Stock issuable upon exercise of Warrants.


Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by certain investment funds it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset
Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen may be deemed to
beneficially own 3,230,434 shares of Common Stock and, subject to a beneficial ownership limitation provision described below (the “Blocker”), up to 3,000,000 shares of Common Stock issuable upon the exercise of Warrants (together constituting, after taking into account the Blocker, 9.99% of the outstanding shares of Common Stock). Each of Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen disclaims beneficial ownership of any of the securities covered by this statement.
The percentage set forth in the preceding paragraph and in Row 11 of the cover page for each reporting person is based on 8,197,462 shares of Common Stock outstanding as of November 1, 2019, as represented in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission on November 12, 2019, plus an additional 30,250,000 shares of Common Stock issued in the Issuer’s recently completed public offering and assumes, subject to the Blocker, the exercise of the Warrants beneficially owned by the reporting persons.
The Warrants reflected on the cover pages are subject to a 9.99% Blocker provision whereby they are not exercisable to the extent doing so would, taking into account all other shares of Common Stock beneficially owned by the reporting persons, result in beneficial ownership in the Common Stock of the Issuer in excess of 9.99% of the Issuer’s outstanding Common Stock, as calculated in a manner consistent with the provisions of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. Consequently, as of the date of the event which requires the filing of this statement, some of the Warrants referred to herein are not presently exercisable due to the Blocker.
Item 5. Ownership of 5 Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following [].

Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable

Item 7.  Identification and Classification of the Subsidiary Which Acquired
the Security Being Reporting on by the Parent Holding Company or Control
Person.
Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9.  Notice of Dissolution of Group.

Not applicable

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or
as a participant in any transaction having that purpose or effect.

Signature.  After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Dated: November 26, 2019

POINT72 ASSET MANAGEMENT, L.P.
By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

POINT72 CAPITAL ADVISORS, INC.
By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

STEVEN A. COHEN
By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person

Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Onconova Therapeutics Charts.

Onconova Therapeutics (NASDAQ:ONTX)
Intraday Stock Chart

Today : Monday 9 December 2019

Click Here for more Onconova Therapeutics Charts.

Latest ONTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191210 01:18:59